Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Antiangiogenic strategies in pancreatic cancer.

Riess H.

Recent Results Cancer Res. 2008;177:123-9. Review.

PMID:
18084954
2.

Anti-angiogenesis therapy in pancreatic carcinoma.

Saif MW.

JOP. 2006 Mar 9;7(2):163-73. Review.

4.

Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.

Bocci G, Danesi R, Marangoni G, Fioravanti A, Boggi U, Esposito I, Fasciani A, Boschi E, Campani D, Bevilacqua G, Mosca F, Del Tacca M.

Eur J Pharmacol. 2004 Sep 13;498(1-3):9-18.

PMID:
15363970
5.

The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer.

Awasthi N, Yen PL, Schwarz MA, Schwarz RE.

J Cell Biochem. 2012 Mar;113(3):784-91. doi: 10.1002/jcb.23405.

PMID:
22020918
6.

Clinical trials of VEGF receptor tyrosine kinase inhibitors in pancreatic cancer.

Cabebe E, Fisher GA.

Expert Opin Investig Drugs. 2007 Apr;16(4):467-76. Review.

PMID:
17371195
7.
8.

Antiangiogenic therapy in malignant glioma: promise and challenge.

Sathornsumetee S, Rich JN.

Curr Pharm Des. 2007;13(35):3545-58. Review.

PMID:
18220791
9.

Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer.

Troiani T, Martinelli E, Orditura M, De Vita F, Ciardiello F, Morgillo F.

Expert Opin Investig Drugs. 2012 Jul;21(7):949-59. doi: 10.1517/13543784.2012.689287. Epub 2012 May 22. Review.

PMID:
22612461
10.

The potential of antiangiogenic therapy in non-small cell lung cancer.

Giaccone G.

Clin Cancer Res. 2007 Apr 1;13(7):1961-70. Review.

11.

Anti-angiogenic agents in pancreatic cancer: a review.

Assifi MM, Hines OJ.

Anticancer Agents Med Chem. 2011 Jun;11(5):464-9. Review.

PMID:
21521158
12.

Molecular basis of the synergistic antiangiogenic activity of bevacizumab and mithramycin A.

Jia Z, Zhang J, Wei D, Wang L, Yuan P, Le X, Li Q, Yao J, Xie K.

Cancer Res. 2007 May 15;67(10):4878-85.

13.

Target therapies in pancreatic carcinoma.

Silvestris N, Gnoni A, Brunetti AE, Vincenti L, Santini D, Tonini G, Merchionne F, Maiello E, Lorusso V, Nardulli P, Azzariti A, Reni M.

Curr Med Chem. 2014;21(8):948-65. Review.

PMID:
23992319
14.

[Angiogenesis and breast cancer].

Bachelot T, Ray-Coquard I, Cassier P, Blay JY.

Bull Cancer. 2007 Jul;94 Spec No:S203-10. Review. French.

PMID:
17846006
15.

Molecular therapy in pancreatic adenocarcinoma.

MacKenzie MJ.

Lancet Oncol. 2004 Sep;5(9):541-9. Review.

PMID:
15337483
16.

Novel approaches to target pancreatic cancer.

Porzner M, Seufferlein T.

Curr Cancer Drug Targets. 2011 Jul;11(6):698-713. Review.

PMID:
21599630
17.

VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials.

Lambrechts D, Claes B, Delmar P, Reumers J, Mazzone M, Yesilyurt BT, Devlieger R, Verslype C, Tejpar S, Wildiers H, de Haas S, Carmeliet P, Scherer SJ, Van Cutsem E.

Lancet Oncol. 2012 Jul;13(7):724-33. doi: 10.1016/S1470-2045(12)70231-0. Epub 2012 May 17.

PMID:
22608783
18.

[The importance of angiogenesis in pancreatic cancer].

Myƛliwiec P, Dadan J.

Przegl Lek. 2009;66(3):155-8. Review. Polish.

PMID:
19689042
19.

Expanding the clinical development of bevacizumab.

Chen HX.

Oncologist. 2004;9 Suppl 1:27-35. Review.

20.

Therapeutic inhibition of Sp1 expression in growing tumors by mithramycin a correlates directly with potent antiangiogenic effects on human pancreatic cancer.

Yuan P, Wang L, Wei D, Zhang J, Jia Z, Li Q, Le X, Wang H, Yao J, Xie K.

Cancer. 2007 Dec 15;110(12):2682-90.

Supplemental Content

Support Center